AAAAAA

   
Results: 1-25 | 26-33
Results: 1-25/33
ACE inhibitors to prevent end-stage renal disease: When to start and why possibly never to stop: A post hoc analysis of the REIN trial results
Authors: Ruggenenti, P Perna, A Remuzzi, G
Citation: P. Ruggenenti et al., ACE inhibitors to prevent end-stage renal disease: When to start and why possibly never to stop: A post hoc analysis of the REIN trial results, J AM S NEPH, 12(12), 2001, pp. 2832-2837
Thrombotic microangiopathies in the intensive care unit: Many questions, some answers
Authors: Ruggenenti, P Aros, C Remuzzi, G
Citation: P. Ruggenenti et al., Thrombotic microangiopathies in the intensive care unit: Many questions, some answers, CONTR NEPHR, 132, 2001, pp. 53-67
Chronic renal disease - Reply
Authors: Ruggenenti, P Schieppati, A Remuzzi, G
Citation: P. Ruggenenti et al., Chronic renal disease - Reply, LANCET, 358(9286), 2001, pp. 1012-1012
Progression, remission, regression of chronic renal diseases
Authors: Ruggenenti, P Schieppati, A Remuzzi, G
Citation: P. Ruggenenti et al., Progression, remission, regression of chronic renal diseases, LANCET, 357(9268), 2001, pp. 1601-1608
Drug-induced thrombotic microangiopathy - Incidence, prevention and management
Authors: Pisoni, R Ruggenenti, P Remuzzi, G
Citation: R. Pisoni et al., Drug-induced thrombotic microangiopathy - Incidence, prevention and management, DRUG SAFETY, 24(7), 2001, pp. 491-501
Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura
Authors: Ruggenenti, P Noris, M Remuzzi, G
Citation: P. Ruggenenti et al., Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura, KIDNEY INT, 60(3), 2001, pp. 831-846
Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease
Authors: Jafar, TH Stark, PC Schmid, CH Landa, M Maschio, G Marcantoni, C de Jong, PE de Zeeuw, D Shahinfar, S Ruggenenti, P Remuzzi, G Levey, AS
Citation: Th. Jafar et al., Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease, KIDNEY INT, 60(3), 2001, pp. 1131-1140
Post-transplant renal artery stenosis: The hemodynamic response to revascularization
Authors: Ruggenenti, P Mosconi, L Bruno, S Remuzzi, A Sangalli, F Lepre, MS Agazzi, R Nani, R Fasolini, G Remuzzi, G
Citation: P. Ruggenenti et al., Post-transplant renal artery stenosis: The hemodynamic response to revascularization, KIDNEY INT, 60(1), 2001, pp. 309-318
Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies
Authors: Ruggenenti, P Pagano, E Tammuzzo, L Benini, R Garattini, L Remuzzi, G
Citation: P. Ruggenenti et al., Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies, KIDNEY INT, 59(1), 2001, pp. 286-294
Remission achieved in chronic nephropathy by a multidrug approach targetedat urinary protein excretion
Authors: Ruggenenti, P Brenner, BM Remuzzi, G
Citation: P. Ruggenenti et al., Remission achieved in chronic nephropathy by a multidrug approach targetedat urinary protein excretion, NEPHRON, 88(3), 2001, pp. 254-259
Renoprotective therapy in patients with nondiabetic nephropathies
Authors: Pisoni, R Ruggenenti, P Remuzzi, G
Citation: R. Pisoni et al., Renoprotective therapy in patients with nondiabetic nephropathies, DRUGS, 61(6), 2001, pp. 733-745
Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: Differences between women and men in relation to the ace gene polymorphism (vol 11, pg 88, 2000)
Authors: Ruggenenti, P
Citation: P. Ruggenenti, Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: Differences between women and men in relation to the ace gene polymorphism (vol 11, pg 88, 2000), J AM S NEPH, 11(5), 2000, pp. NIL_67-NIL_67
Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: Differences between women and men in relation to the ACE gene polymorphism
Authors: Ruggenenti, P Perna, A Zoccali, C Gherardi, G Benini, R Testa, A Remuzzi, G
Citation: P. Ruggenenti et al., Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: Differences between women and men in relation to the ACE gene polymorphism, J AM S NEPH, 11(1), 2000, pp. 88-96
Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment?
Authors: Ruggenenti, P Remuzzi, G
Citation: P. Ruggenenti et G. Remuzzi, Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment?, NEPH DIAL T, 15(12), 2000, pp. 1900-1902
Chronic proteinuric nephropathies: Outcomes and response to treatment in aprospective cohort of 352 patients with different patterns of renal injury
Authors: Ruggenenti, P Perna, A Gherardi, G Benini, R Remuzzi, G
Citation: P. Ruggenenti et al., Chronic proteinuric nephropathies: Outcomes and response to treatment in aprospective cohort of 352 patients with different patterns of renal injury, AM J KIDNEY, 35(6), 2000, pp. 1155-1165
ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome
Authors: Ruggenenti, P Mosconi, L Vendramin, G Moriggi, M Remuzzi, A Sangalli, F Remuzzi, G
Citation: P. Ruggenenti et al., ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome, AM J KIDNEY, 35(3), 2000, pp. 381-391
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials
Authors: Neal, B MacMahon, S Chapman, N Cutler, J Fagard, R Neal, B Whelton, P Yusuf, S Agodoa, L Baigent, C Black, H Boissel, JP Brenner, B Brown, M Bulpitt, C Byington, R Chalmers, J Collins, R Dahlof, B Davis, B Estacio, R Fox, K Hansson, L Holman, R Hunsicker, L Kostis, J Kuramoto, K Kusek, J Lees, R Lewis, E Lindholm, LH Liu, L Lubsen, J Malacco, E Mancia, G Martin, I Pepine, C Pfeffer, M Pitt, B Poole-Wilson, P Remuzzi, G Rodgers, A Ruggenenti, P Schrier, R Sever, P Sleight, P Staessen, J Teo, K Turner, R Wing, L Zanchetti, A Algert, C Woodward, M
Citation: B. Neal et al., Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials, LANCET, 356(9246), 2000, pp. 1955-1964
Pretreatment blood pressure reliably predicts progression of chronic nephropathies
Authors: Ruggenenti, P Perna, A Lesti, M Pisoni, R Mosconi, L Arnoldi, F Ciocca, I Gaspari, F Remuzzi, G
Citation: P. Ruggenenti et al., Pretreatment blood pressure reliably predicts progression of chronic nephropathies, KIDNEY INT, 58(5), 2000, pp. 2093-2101
Endothelin antagonists in renal disease
Authors: Benigni, A Madias, NE Remuzzi, G Siragy, HM Brooks, DP Rossi, GP Abbate, M Ong, A Loeffler, BM Bender, N Noris, M Ruggenenti, P Wilson, C
Citation: A. Benigni et al., Endothelin antagonists in renal disease, KIDNEY INT, 57(4), 2000, pp. 1778-1794
ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies
Authors: Perna, A Ruggenenti, P Testa, A Spoto, B Benini, R Misefari, V Remuzzi, G Zoccali, C
Citation: A. Perna et al., ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies, KIDNEY INT, 57(1), 2000, pp. 274-281
The role of protein traffic in the progression of renal diseases
Authors: Ruggenenti, P Remuzzi, G
Citation: P. Ruggenenti et G. Remuzzi, The role of protein traffic in the progression of renal diseases, ANN R MED, 51, 2000, pp. 315-327
Renal transplantation: Single or dual for donors aging >= 60 years?
Authors: Remuzzi, G Ruggenenti, P
Citation: G. Remuzzi et P. Ruggenenti, Renal transplantation: Single or dual for donors aging >= 60 years?, TRANSPLANT, 69(10), 2000, pp. 2000-2001
Unrecognized pattern of von Willebrand factor abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura
Authors: Galbusera, M Benigni, A Paris, S Ruggenenti, P Zoja, C Rossi, C Remuzzi, G
Citation: M. Galbusera et al., Unrecognized pattern of von Willebrand factor abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, J AM S NEPH, 10(6), 1999, pp. 1234-1241
In chronic nephropathies prolonged ACE inhibition can induce remission: Dynamics of time-dependent changes in GFR
Authors: Ruggenenti, P Perna, A Benini, R Bertani, T Zoccali, C Maggiore, Q Salvadori, M Remuzzi, G
Citation: P. Ruggenenti et al., In chronic nephropathies prolonged ACE inhibition can induce remission: Dynamics of time-dependent changes in GFR, J AM S NEPH, 10(5), 1999, pp. 997-1006
Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Role of factor H abnormalities
Authors: Noris, M Ruggenenti, P Perna, A Orisio, S Caprioli, J Skerka, C Vasile, B Zipfel, PF Remuzzi, G
Citation: M. Noris et al., Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Role of factor H abnormalities, J AM S NEPH, 10(2), 1999, pp. 281-293
Risultati: 1-25 | 26-33